Introduction
The major contribution of platelets to the formation of intravascular thrombi has stimulated the search for agents capable of inhibiting platelet aggregation. The effect of the pyrimido-pyrimidine derivatives, dipyridamole and RA433, on platelet behaviour in vivo and in vitro has been extensively studied. Dipyridamole inhibits both platelet aggregation in vitro (Emmons et al., 1965a; Gray et al., 1968) and thrombus formation at sites of vascular injury in experimental animals (Emmons et al., 1965b) . Dipyridamole has also been shown to be of therapeutic value ; Sullivan et al., (1968) reported a significant decrease of thromboembolic incidents in patients with prosthetic heart valve replacement treated with combined dipyridamole and anticoagulant therapy, compared with those treated with anticoagulants alone. RA433 is a more powerful inhibitor of platelet aggregation in vitro than dipyridamole (Forbes et al., 1969) , but differs from dipyridamole in that thrombus formation in vivo in experimental animals is uninfluenced (Elkeles et al., 1968) . Clinical evaluation of RA433 is awaited.
A new derivative of pyrimido-pyrimidine, RA233, is now available, and its effect on human platelet behaviour in vitro is reported in this study. The activity of RA233 is compared with that of its analogue RA433. 
Methods
The methods are described in detail by Forbes et al. (1969) .
Chandler Tube Technique.-The method used was that described by Chandler (1958) as modified by Cunningham et al. (1965) .
Turbidimetric Method.-The turbidimetric method of Born (1962) was modified as described by Hassanein (1969) Whole Blood Clot Retraction.-A modification of the method described by Dacie (1956) Dacie (1956) . Experiments without A.D.P. were performed and the results compared.
Platelet counts were performed with formal citrate as the diluting fluid (Dacie, 1956 Release of Platelet Factor 3 by Kaolin.-RA233 and RA433 significantly inhibited the release of platelet factor 3 induced by kaolin (Fig. 4) . Neither drug affected the clotting-times when platelet-poor plasma was used, indicating that they had no inhibitory effect on plasma coagulation factors. (Fig. 5) . There was no significant difference between the two drugs in this activity (P>0-1). Plasma clot retraction (platelet-rich plasma) was significantly diminished by both drugs (Fig. 6) . The addition of A.D.P. before recalcification partially corrected the inhibition of clot retraction produced by RA233 (P<0.02) but had no significant effect in that produced by RA433 (P>0-1). Discussion Interest in the pyrimido-pyrimidine group of compounds has been stimulated by the potential therapeutic value in occlusive vascular disease of substances which reduce platelet stickiness. There is considerable evidence that adherence of platelets to one another-and to vessel walls at sites of endothelial inury is a fundamental step in the formation of intravascular thrombi (Mustard et al., 1962) . The initial aggregation of platelets is independent of blood coagulation (Jprgensen and Borchgrevink, 1964; Mustard et al. 1964 ) and may be brought about by the release of A.D.P. from the injured tissue (Honour and-Mitchell, 1963; Born et al., 1964) . The release of additional A.D.P. and of platelet factor 3, and the subsequent generation of thrombin, leads to stabilization of the thrombus with fibrin formation.
Hitherto, the main medical approach to the treatment of thromboembolic disease has been anticoagulant therapy, but the benefits to be gained by the use of anticoagulants in arterial thrombosis remain controversial after 20 years of largescale clinical trial. The quest for drugs -to reduce platelet adhesiveness is a logical step in therapeutic research. The pyrimido-pyrimidine derivatives, dipyridamole (Emmons et al., 1965a (Emmons et al., , 1965b Gray et al, 1968) and RA433 (Elkeles et al., 1968; Forbes. et al., 1969) , have been shown to reduce platelet adhesiveness/aggregation in vivo and in vitro. They have, however, differing actions in the injured artery model in experimental animals. Dipyridamole inhibits thrombus formation whereas RA433 is ineffective (Elkeles et al., 1968) . Sullivan et al. (1968) showed that dipyridamole is therapeutically effective when combined with anticoagulants in reducing the number of thromboembolic incidents in patients with prosthetic heart valves compared with those treated with anticoagulants alone.
Dipyridamole and RA433 have the advantage that they are active after oral administration and that they are relatively free from side-effects (Elkeles et Gray et al., 1968 The results show that RA233 has-properties similar to dipyridamole and RA433 in altering platelet behaviour in vitro, but is significantly more potent when tested in some in-vitro models. RA233 is well absorbed by mouth and relatively non-toxic when administered to experimental animals (R. Kadatz, personal communication, 1969 
